Gilead Sciences, Inc. (NASDAQ:GILD) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a report released on Friday.

Several other research firms have also recently weighed in on GILD. Credit Suisse Group AG cut their price objective on Gilead Sciences from $93.00 to $79.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 8th. Barclays PLC reissued a “buy” rating on shares of Gilead Sciences in a research report on Thursday, February 9th. Berenberg Bank set a $78.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, February 14th. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $79.63 price objective on the stock in a research report on Tuesday, March 7th. Finally, Zacks Investment Research cut Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Monday, February 13th. Twelve analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and an average target price of $80.61.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ GILD) traded down 0.92% during midday trading on Friday, reaching $64.88. The company had a trading volume of 1,867,797 shares. Gilead Sciences has a 12-month low of $63.88 and a 12-month high of $88.85. The stock’s 50 day moving average is $66.19 and its 200 day moving average is $69.73. The firm has a market capitalization of $84.78 billion, a price-to-earnings ratio of 6.86 and a beta of 1.11.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.18 by $0.02. Gilead Sciences had a return on equity of 92.36% and a net margin of 44.43%. The business had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.66 billion. Equities research analysts expect that Gilead Sciences will post $8.21 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 29th. Stockholders of record on Friday, June 16th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date of this dividend is Wednesday, June 14th. Gilead Sciences’s payout ratio is currently 18.91%.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/06/06/valuengine-downgrades-gilead-sciences-inc-gild-to-hold.html.

In other news, Director John Francis Cogan sold 9,943 shares of the company’s stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total value of $668,666.75. Following the completion of the transaction, the director now directly owns 47,562 shares in the company, valued at approximately $3,198,544.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $67.18, for a total value of $4,926,510.94. Following the completion of the transaction, the insider now owns 3,199,969 shares of the company’s stock, valued at $214,973,917.42. The disclosure for this sale can be found here. Insiders sold a total of 88,276 shares of company stock valued at $5,932,578 over the last quarter. Company insiders own 1.40% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Pathstone Family Office LLC boosted its position in Gilead Sciences by 12,906.7% in the third quarter. Pathstone Family Office LLC now owns 62,172 shares of the biopharmaceutical company’s stock worth $5,372,000 after buying an additional 61,694 shares during the last quarter. Lipe & Dalton boosted its position in Gilead Sciences by 33.3% in the third quarter. Lipe & Dalton now owns 38,725 shares of the biopharmaceutical company’s stock worth $3,064,000 after buying an additional 9,675 shares during the last quarter. Korea Investment CORP boosted its position in Gilead Sciences by 4.9% in the third quarter. Korea Investment CORP now owns 1,646,269 shares of the biopharmaceutical company’s stock worth $130,253,000 after buying an additional 76,745 shares during the last quarter. Advisor Group Inc. boosted its position in Gilead Sciences by 6.4% in the third quarter. Advisor Group Inc. now owns 180,258 shares of the biopharmaceutical company’s stock worth $14,034,000 after buying an additional 10,827 shares during the last quarter. Finally, Windsor Capital Management LLC purchased a new position in Gilead Sciences during the third quarter worth about $644,000. Hedge funds and other institutional investors own 74.19% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.